David McIntosh: Heart-warming and Life-saving! Sky’s Contribution is Enormously Important
David McIntosh, Founder and Chair of United Plasma Action, reposted from NHS Blood and Transplant on LinkedIn:
”Heart-warming AND life-saving!!
Sky’s contribution is enormously important.
Are all the other Media companies doing similar things?
Are all UK employers with large high-employment sites welcoming cooperation with their local Blood Transfusion Services??
If not, why not ???? ????”
NHS Blood and Transplant shared on LinkedIn:
”Proving the Sky really is the limit when it comes to generosity!
We were delighted to team up once again with Sky at the start of September, hosting ‘What’s Your Blood Type?’ events at the company’s Isleworth office.
Over two days, we had the pleasure of meeting more than 1,500 members of staff, many of whom discovered their blood types and how their donations could be used to save lives.
The results were fantastic:
- 155 Sky colleagues signed up to become plasma donors
- 85 registered to become blood donors
- 72 appointments already booked
We’re proud to have partnered with Sky over the last two years, helping us reach new donors and raise awareness.
Huge thanks to our champion Bayley Thomas at Sky, who’s been brilliant in supporting these events.
Bayley says: “At Sky, we’re incredibly proud of our partnership with NHS Blood and Transplant.
Through the What’s Your Blood Type? events, we’ve not only raised awareness of the vital need for blood and plasma donations and shone a light on conditions like sickle cell, but also inspired action.”
Aditya Raj, our Plasma Engagement Manager, adds: “We’re hugely thankful to have the continued support of Sky.
This month’s event was our third with the company, with each delivering huge enthusiasm and registration numbers among staff.”
To everyone at Sky who joined us, asked questions, registered, and booked appointments – you’re absolute stars!”
Stay updated with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals